マイクロRNA（miRNA）の世界市場

マイクロRNA（miRNA）の世界市場は2030年までに8億4,080万米ドルに達する

2022年に2億8,260万米ドルと推定されるマイクロRNA（miRNA）の世界市場は、2022年から2030年にかけて14.6%のCAGRで成長し、2030年には8億4,080万米ドルに達すると予測されます。本レポートで分析されているセグメントの一つである製品は、CAGR 12.9%を記録し、分析期間終了時には4億1,960万米ドルに達すると予測されています。サービス分野の成長は、今後8年間のCAGRが16.5％と予測されています。

米国市場は1億2,050万米ドル、中国はCAGR18.6％で成長すると予測

米国のマイクロRNA（miRNA）市場は、2022年には1億2,050万米ドルになると推定されます。世界第2位の経済大国である中国は、2022年から2030年までの分析期間においてCAGR 18.6%で推移し、2030年までに9,990万米ドルの市場規模に達すると予測されています。その他の注目すべき地理的市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ12.8%と13.5%の成長が予測されています。欧州では、ドイツがCAGR約13.2%で成長すると予測されています。

調査対象企業の例

• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Abcam PLC
• BioVendor-Laboratorni medicina a.s
• GeneCopoeia, Inc.
• AKESOgen, Inc.
• Entos Pharmaceuticals
• Genomnia
• Guangzhou Ruibo Biotechnology Co., Ltd.
• 20Med Therapeutics
• AceRNA Technologies Co., Ltd.
• AptamiR Therapeutics
• Causeway Therapeutics
• Cardior Pharmaceuticals
• Craif

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• miRNAアプリケーションについての洞察
• がん
• 心臓病
• 腎臓病
• 神経系
• アルコール依存症
• 肥満
• 止血
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• 世界のその他の地域

第4章 競合

What`s New?

» Special discussions on the global economic climate and market sentiment

» Coverage on global competitiveness and key competitor percentage market shares

» Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial

» Online interactive peer-to-peer collaborative bespoke updates

» Access to our digital archives and MarketGlass™ research platform

» Complimentary updates for one year

» Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes

Economic Outlook

The global economic outlook is improving, and growth recovery, albeit on the lower side, is expected for this year and the next. The United States although witnessing slowing GDP growth in response to tight monetary and financial conditions, has nevertheless overcome the recession threat. Easing of headline inflation in Euro area is helping boost real incomes and is contributing to pick-up in economic activity. China is expected to see strong increases in GDP in the coming year as the pandemic threat recedes and the government sheds its zero-COVID policy. With optimistic GDP projections, India remains on-course to emerge into a US$6 trillion economy by 2030, surpassing Japan and Germany.

The upturn, however, remains fragile and a number of interlocking challenges continue to run in parallel, such as continued uncertainty around the war in Ukraine; slower than expected decline in global headline inflation; continuation of food and fuel inflation as a persistent economic problem for most developing countries; and still high retail inflation and its impact on consumer confidence and spending. Countries and their governments are showing signs of weathering these challenges, which helps lift market sentiments. As governments continue to combat inflation to get it down to more economically conformable levels by raising interest rates, new job creation will slowdown and impact economic activity. Stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced.

Although corporate investments can likely be held back by inflation worries and weaker demand, rise of new technologies will reverse partially this prevailing investment sentiment. Rise of generative AI; applied AI; industrializing machine learning; next-generation software development; Web3; cloud and edge computing; quantum technologies; electrification and renewables and climate technologies beyond electrification and renewables, will open up the global investment landscape. The technologies hold the potential to drive sizeable incremental growth and value to global GDP in the coming years. The short-term is expected to be a mixed bag of challenges and opportunities for both consumers and investors alike. There is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global microRNA (miRNA) Market to Reach $840.8 Million by 2030

The global market for microRNA (miRNA) estimated at US$282.6 Million in the year 2022, is projected to reach a revised size of US$840.8 Million by 2030, growing at a CAGR of 14.6% over the period 2022-2030. Products, one of the segments analyzed in the report, is projected to record 12.9% CAGR and reach US$419.6 Million by the end of the analysis period. Growth in the Services segment is estimated at 16.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $120.5 Million, While China is Forecast to Grow at 18.6% CAGR

The microRNA (miRNA) market in the U.S. is estimated at US$120.5 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$99.9 Million by the year 2030 trailing a CAGR of 18.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.8% and 13.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 13.2% CAGR.

Select Competitors (Total 64 Featured) -

• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Abcam PLC
• BioVendor - Laboratorni medicina a.s
• GeneCopoeia, Inc.
• AKESOgen, Inc.
• Entos Pharmaceuticals
• Genomnia
• Guangzhou Ruibo Biotechnology Co., Ltd.
• 20Med Therapeutics
• AceRNA Technologies Co., Ltd.
• AptamiR Therapeutics
• Causeway Therapeutics
• Cardior Pharmaceuticals
• Craif

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • microRNA (miRNA) - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • A Prelude to MicroRNA
  • Impact of Covid-19 and a Looming Global Recession
  • 2020 Marked as a Year of Disruption & Transformation
  • As the Race between the Virus & Vaccines Intensifies, Where is the World Economy Headed in 2021
  • World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
  • COVID-19 Impact on mRNA Market
  • Global Market Prospects and Outlook
  • Global miRNA Market Set to Witness Rapid Growth
  • Disease Diagnostics Segment Leads the Market
  • MicroRNAs Likely to Be Instrumental in Disease Diagnosis and Treatment
  • Polymerase Chain Reaction (PCR) Dominates the Instruments Category
  • Academic and Government Research Institutes Holds the Largest Share
  • North America Dominates Global miRNA Market, Asia-Pacific to Witness Steady Growth
  • Competition
  • Increasing Emphasis on R&D by Players to Boost Market Growth
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Incidence of Infectious Diseases and Chronic Conditions to Help miRNA Market Gallop Ahead
  • Fatalities by Heart Conditions: Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
  • Increasing Application in Cancer Diagnostics as Biomarkers to Drive Market Growth
  • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Breakdown of Total Number of Cancer Cases by Region: 2020
  • Breakdown of Total Number of Cancer Cases by Type: 2020
  • The Future of miRNA-based Cancer Biomarkers
  • Consistent Increase in Risks and Threats from Infections Drive Healthy Market Growth
  • Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
  • Infection Rates of Viruses ((per infected person)) Involved in Outbreaks Worldwide: 2020
  • Infectious Diseases Related Mortality High Among Children below 5 Years: Breakdown of Leading Causes of Death in Children below 5 Years (in %)
  • MicroRNA Biomarkers Hold Promise for Diagnosis of Infectious Diseases
  • Focus on Development of miRNA-based Therapeutics Bodes Well for Market Growth
  • Increasing Investments in miRNA to Bolster Market Growth
  • Diagnostics and Therapeutics Investments
  • Standard Methods Utilized to measure miRNA Biomarkers
  • Advancements in Detection Methodologies Focus on Enhancing Sensitivity and Selectivity of miRNA Detection
  • Increasing Demand for Liquid Biopsies to Drive the MicroRNA Market
  • miRNA by Type of Gastrointestinal Cancers
  • Circulating miRNAs as Cancer Detectors
  • Aging Demographics Add to the Global Burden of Chronic Diseases, Presenting Opportunities for the Market
  • Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030
  • Growing Global Healthcare Spending and Supportive Government Initiatives Boost Market Prospects
  • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
  • Per Capita Healthcare Expenditure (in $) by Select Countries for 2018
  • miRNA and Next Generation Sequencing
  • Market Restraints
• AN INSIGHT INTO MIRNA APPLICATIONS
• CANCER
  • Role of miRNA in Cancer Cell
  • DNA Repair and Cancer
• HEART DISEASE
  • miRNA-712
  • Human Homolog-microRNA-205
• KIDNEY DISEASE
• NERVOUS SYSTEM
  • Stroke
• ALCOHOLISM
• OBESITY
• HEMOSTASIS
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for microRNA (miRNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 2: World Historic Review for microRNA (miRNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 3: World 14-Year Perspective for microRNA (miRNA) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2016, 2023 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 6: World 14-Year Perspective for Products by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2023 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 9: World 14-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2023 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 12: World 14-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2023 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 15: World 14-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2023 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Immunological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Immunological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 18: World 14-Year Perspective for Immunological Disorders by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2023 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 21: World 14-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2023 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Neurological Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 24: World 14-Year Perspective for Neurological Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2023 & 2030
  • TABLE 25: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 26: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 27: World 14-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2023 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 29: World Historic Review for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 30: World 14-Year Perspective for Academic & Government Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2023 & 2030
  • TABLE 31: World Recent Past, Current & Future Analysis for Biotech & Pharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 32: World Historic Review for Biotech & Pharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 33: World 14-Year Perspective for Biotech & Pharma Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2023 & 2030
  • TABLE 34: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 35: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 36: World 14-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2023 & 2030
  • TABLE 37: World microRNA (miRNA) Market Analysis of Annual Sales in US$ Thousand for Years 2016 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 40: USA 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2023 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 43: USA 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2023 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 46: USA 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2023 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 49: Canada 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2023 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 52: Canada 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2023 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 55: Canada 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2023 & 2030
• JAPAN
  • microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 58: Japan 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2023 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 61: Japan 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2023 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 64: Japan 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2023 & 2030
• CHINA
  • microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 66: China Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 67: China 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2023 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 69: China Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 70: China 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2023 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 72: China Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 73: China 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2023 & 2030
• EUROPE
  • microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2022 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for microRNA (miRNA) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 76: Europe 14-Year Perspective for microRNA (miRNA) by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2016, 2023 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 79: Europe 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2023 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 82: Europe 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2023 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 85: Europe 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2023 & 2030
• FRANCE
  • microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 87: France Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 88: France 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2023 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 90: France Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 91: France 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2023 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 93: France Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 94: France 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2023 & 2030
• GERMANY
  • microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 97: Germany 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2023 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 100: Germany 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2023 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 103: Germany 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2023 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 106: Italy 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2023 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 109: Italy 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2023 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 112: Italy 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2023 & 2030
• UNITED KINGDOM
  • microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 115: UK 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2023 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 118: UK 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2023 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 121: UK 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2023 & 2030
• REST OF EUROPE
  • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 123: Rest of Europe Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 124: Rest of Europe 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2023 & 2030
  • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 126: Rest of Europe Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 127: Rest of Europe 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2023 & 2030
  • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 129: Rest of Europe Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 130: Rest of Europe 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2023 & 2030
• ASIA-PACIFIC
  • microRNA (miRNA) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 132: Asia-Pacific Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 133: Asia-Pacific 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2023 & 2030
  • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 135: Asia-Pacific Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 136: Asia-Pacific 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2023 & 2030
  • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 138: Asia-Pacific Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 139: Asia-Pacific 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2023 & 2030
• REST OF WORLD
  • TABLE 140: Rest of World Recent Past, Current & Future Analysis for microRNA (miRNA) by Type - Products and Services - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 141: Rest of World Historic Review for microRNA (miRNA) by Type - Products and Services Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 142: Rest of World 14-Year Perspective for microRNA (miRNA) by Type - Percentage Breakdown of Value Revenues for Products and Services for the Years 2016, 2023 & 2030
  • TABLE 143: Rest of World Recent Past, Current & Future Analysis for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 144: Rest of World Historic Review for microRNA (miRNA) by Application - Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 145: Rest of World 14-Year Perspective for microRNA (miRNA) by Application - Percentage Breakdown of Value Revenues for Cancer, Infectious Diseases, Immunological Disorders, Cardiovascular Diseases, Neurological Diseases and Other Applications for the Years 2016, 2023 & 2030
  • TABLE 146: Rest of World Recent Past, Current & Future Analysis for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • TABLE 147: Rest of World Historic Review for microRNA (miRNA) by End-Use - Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2021 and % CAGR
  • TABLE 148: Rest of World 14-Year Perspective for microRNA (miRNA) by End-Use - Percentage Breakdown of Value Revenues for Academic & Government Research Institutes, Biotech & Pharma Companies and Other End-Uses for the Years 2016, 2023 & 2030

IV. COMPETITION